348 related articles for article (PubMed ID: 11647660)
41. Data monitoring committees: the moral case for maximum feasible independence.
Walters L
Stat Med; 1993 Mar; 12(5-6):575-80. PubMed ID: 11659537
[No Abstract] [Full Text] [Related]
42. Twice wrong on AIDS.
Gieringer D
N Y Times Web; 1987 Jan; ():A21. PubMed ID: 11646161
[No Abstract] [Full Text] [Related]
43. Character and the ethical conduct of research.
Pellegrino ED
Account Res; 1992; 2(1):1-11. PubMed ID: 11651456
[No Abstract] [Full Text] [Related]
44. Policies and quality assurance in the pharmaceutical industry.
Shamoo AE
Account Res; 1991; 1(4):273-84. PubMed ID: 11651459
[No Abstract] [Full Text] [Related]
45. Reviewing subject recruitment: new rules from Rockville.
McMahon FG
IRB; 1988; 10(3):6-7. PubMed ID: 11651911
[No Abstract] [Full Text] [Related]
46. Trials on trial.
Wuethrich B
New Sci; 1994 May; 142(1927):14-5. PubMed ID: 11656346
[No Abstract] [Full Text] [Related]
47. For the uninsured, drug trials are health care.
Kolata G; Eichenwald K
N Y Times Web; 1999 Jun; ():A1, C12. PubMed ID: 11647664
[No Abstract] [Full Text] [Related]
48. Why I oppose drug company payment of physician/investigators on a per patient/subject basis.
Roizen R
IRB; 1988; 10(1):9-10. PubMed ID: 11658990
[No Abstract] [Full Text] [Related]
49. Considering experimentation and elusive truth: informed consent made difficult.
Brodeur D
Issues (St Louis Mo); 1992; 7(2):1-8. PubMed ID: 11659444
[No Abstract] [Full Text] [Related]
50. Competing interests: the need to control conflict of interests in biomedical research.
Steiner D
Sci Eng Ethics; 1996 Oct; 2(4):457-68. PubMed ID: 11657732
[No Abstract] [Full Text] [Related]
51. Doctors' offices turn into salesrooms.
Zuger A
N Y Times Web; 1999 Mar; ():F1, F11. PubMed ID: 11647628
[No Abstract] [Full Text] [Related]
52. Ethical issues in funding and monitoring university research.
Beauchamp TL
Bus Prof Ethics J; 1992; 11(1):5-16. PubMed ID: 11659431
[No Abstract] [Full Text] [Related]
53. Calls for strengthened drug-trial guidelines in Japan.
Netley G
Lancet; 1997 Feb; 349(9051):552. PubMed ID: 11654595
[No Abstract] [Full Text] [Related]
54. Patient-funded research: paying the piper or protecting the patient?
Morreim EH
IRB; 1991; 13(3):1-6. PubMed ID: 11651046
[No Abstract] [Full Text] [Related]
55. The concept of the IRB and bureaucratic reality: an exchange of letters.
van Eys J; Levine RJ
IRB; 1984; 6(4):8-10. PubMed ID: 11649563
[No Abstract] [Full Text] [Related]
56. Fraud and misconduct in clinical research: is it prejudicial to patient safety?
Wells F
Adverse Drug React Acute Poisoning Rev; 1992; 11(4):241-55. PubMed ID: 11652183
[No Abstract] [Full Text] [Related]
57. Researchers admit study with drugs had no O.K.
Hilts PJ
N Y Times Web; 1993 Oct; ():B5. PubMed ID: 11646994
[No Abstract] [Full Text] [Related]
58. Physician self-referral and joint venture prohibitions: necessary shield against abusive practices or overregulation?
Baumgartner MR
J Corp Law; 1994; 19(2):313-52. PubMed ID: 11652936
[No Abstract] [Full Text] [Related]
59. Institutional review boards in the university setting: review of pharmaceutical testing protocols, informed consent and ethical concerns.
Kobasic DM
J Coll Univ Law; 1988; 15(2):185-216. PubMed ID: 11659168
[No Abstract] [Full Text] [Related]
60. Researcher denied future U.S. funds.
Broad WJ
Science; 1982 Jun; 216(4550):1081. PubMed ID: 11643749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
